LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Avalo Therapeutics, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERAVTX
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / AVTX COVERAGE

What’s moving Avalo Therapeutics, Inc. now

Current reporting with the operating signal separated from the noise.

01
Stock Titan

Avalo Therapeutics, Inc. SEC Filing (Jul 29, 2026)

The story matters when it changes Avalo Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Why Avalo Therapeutics, Inc. (AVTX) Is Among the Best Low Priced Stocks to Get Rich in 2026

Why Avalo Therapeutics, Inc. (AVTX) Is Among the Best Low Priced Stocks to Get Rich in 2026

Investors are testing whether Avalo Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
03
Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants

Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants

Investors are testing whether Avalo Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Avalo Therapeutics, Inc. Announces Closing of a $31.5 Million Public Offering of Common Stock, Including Proceeds from Exercise of Option to Purchase Additional Shares

Avalo Therapeutics, Inc. Announces Closing of a $31.5 Million Public Offering of Common Stock, Including Proceeds from Exercise of Option to Purchase Additional Shares

Investors are testing whether Avalo Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest AVTX filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-13 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-06 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-23 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-06-23 · Period 2026-06-23SEC ↗8-KMaterial company eventFiled 2026-06-16 · Period 2026-06-16SEC ↗8-KMaterial company eventFiled 2026-06-12 · Period 2026-06-11SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-10 · Period 2026-04-10SEC ↗4Official SEC filingFiled 2026-07-29 · Period 2026-07-27SEC ↗
EARNINGS / QUARTERLY TRACKER

Avalo Therapeutics, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.